Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3550)	4/23/2001 5:08:12 PM
From: Ian@SI	Respond to of 52153

Peter, Couldn't find anything on meticillin or methicillin at Medscape's drug info search. DrKoop.com's drug checker found only Methicillin (it usually is pretty good at finding everything...) Ian. ++++++++++ methicillin Brand: methicillin 1. Hematologic adverse effects reported with methicillin include neutropenia, leukopenia, and thrombocytopenia. Agranulocytosis has been reported rarely. Adverse hematologic effects occur in approximately 7% of treated patients and appear to be associated with higher doses given for long periods of time. Recovery generally occurs within one to two weeks. 2. Methicillin therapy has resulted in transient increases in liver function tests. 3. Hypersensitivity reactions to methicillin include rash (2% to 6%), eosinophilia (up to 38%), pruritis, fever, chills, and myalgias. Methicillin is contraindicated in patients who are allergic to penicillin. 4. Local reactions include thrombophlebitis associated with intravenous administration, and pain at injection site if given intramuscularly. 5. Acute renal failure and interstitial nephritis have been associated with methicillin therapy. These problems occur most frequently after prolonged therapy (longer than ten days). Acute interstitial nephritis may be accompanied by rash, fever, dysuria, proteinuria, eosinophilia, and hematuria. The frequency of acute interstitial nephritis is higher with methicillin than other penicillinase-resistant penicillins and has been reported in up to 17% of patients. Acute renal failure generally occurs after ten days and with doses of methicillin greater than 200 mg/kg/day. Renal function slowly returns towards normal after discontinuation of methicillin, but irreversible decreases in renal function have been observed.

To: Biomaven who wrote (3550)	4/23/2001 6:03:18 PM
From: OpusX	Respond to of 52153

methicillin, no such thing as meticillin Opus

To: Biomaven who wrote (3550)	4/23/2001 6:43:37 PM
From: sim1	Read Replies (1) \| Respond to of 52153

According to the World Drug Index, Meticillin is the "Derwent Preferred Name" ( DPN), the official human-readable name used in the World Drug Index, and Methicillin is the United States Approved Name for the same antibiotic. online.daylight.com:26561/wdi/dxrn/METICILNA.html (Looks like a useful web site)

To: Biomaven who wrote (3550)	4/23/2001 10:29:48 PM
From: Jibacoa	Read Replies (1) \| Respond to of 52153

Re: Staph.Aureus. As reported recently in Internal Medicine News( April 15,2001),at the recent meeting of the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices in Atlanta,GA. Dr. Gary Horwith, NABI's vice president of clinical and medical affairs commented on NABI's StaphVAX. He said that there are about 9 to 11 million at high risk for S.a. infection in the USA. The vaccine is a bivalent conjugate that contains S.a. capsular types 5 & 8, which comprise more than 80% of the disease causing strains. The vaccine was given to 892 patients with end-stage renal disease who were on hemodialysis. There was a control group of 906 similar patients that received placebo injections. At 6 months there were 17 cases of bacteremia due to S.a. in the placebo group vs. 7 in the StaphVAX group.At ten months the numbers were 26 vs.11 showing a 57% reduction in the vaccinated group. The vaccine efficacy got lower by the end of 1 year. which suggests that boosters should be needed every 8 to 9 months. There were no serious vaccine related side effects, only mild to moderate local reactions which usually subsided in 36 to 48 hrs. The vaccine could potentially be used in other high risk patients, including those scheduled for placement of orthopedic devices, pacemakers, indwelling catheters, drainage shunts, etc. Also one or two weeks prior to CABGs or other prolonged surgical procedures. The vaccine induces antibodies that target multiple sites on the bacterial outer coating and that allows the bacteria to be pagocytized by neutrophils. The targeting of multiple sites makes the development of vaccine resistance less likely because the bacteria would have to undergo multiple genetic mutations. siliconinvestor.com Bernard